4basebio PLC
4BB.L is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic products and services.
Business. 4BB.L is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the London Stock Exchange under the ticker 4BB.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4BB.L is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the London Stock Exchange under the ticker 4BB.L. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
The company's capital structure is characterized by a high price-to-book ratio of 285.68, indicating a significant premium over its book value. Its liquidity position is marked by a current ratio of 11.3, suggesting strong short-term liquidity, but it is offset by a negative net cash position after subtracting total debt. The debt-to-equity ratio of 0.58 indicates a moderate level of leverage, with long-term debt amounting to 15,216,000 GBP.
Profitability metrics reveal a challenging financial position. The company reported a net loss of 12,333,000 GBP and an operating loss of 12,042,000 GBP, resulting in a negative return on equity of -46.75% and a negative return on assets of -27.57%. These figures are significantly below the industry norms for profitability and returns, highlighting the company's current financial distress.
Geographically and segment-wise, the company's revenue is not disclosed by region or business segment in the available data. However, the high market capitalization of 7,536,181,230 GBP suggests a concentration of investor expectations in the company's future potential rather than current revenue streams.
The growth trajectory of 4BB.L is uncertain. The company is currently experiencing a significant operating and net loss, with no clear indication of a turnaround in the near term. The absence of positive revenue growth and the high price-to-revenue ratio of 8,093.67 suggest that the company is not currently generating sufficient revenue to support its valuation.
Risk factors include a high liquidity risk due to negative net cash and a negative operating cash flow of 10,744,000 GBP. The company also faces a high credit risk due to its negative operating income and net loss. The risk assessment indicates a medium liquidity risk and a low dilution risk, with no immediate pressure for further equity issuance.
Recent events include a set of analyst estimates that are uniformly high, with a mean price target of 1,800.00 GBP and a mean recommendation of 2.00, indicating a cautious buy stance. However, the lack of strong buy ratings and the presence of only one buy recommendation suggest a lack of strong consensus among analysts regarding the company's future performance.
- 4BB.L is a biotechnology company with a high market capitalization but is currently reporting significant losses.
- The company's financial metrics, including return on equity and return on assets, are negative, indicating poor profitability.
- The company's liquidity position is strong in the short term but is offset by a negative net cash position after subtracting total debt.
- Analysts have a cautious outlook, with a mean price target significantly higher than the current market price.
- The company's growth trajectory is uncertain, with no clear indication of a turnaround in the near term.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,14 |
| Revenue | —no estimate | —no estimate | 1,8M GBP |
| Operating income | —no estimate | —no estimate | -17,7M GBP |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4BB.L Market data — financials · 2026-05-26
- 4Basebio PLC Market data — analyst estimates · 2026-05-26